TNFRSF17 and hematologic disorder: Along with CD19 CAR-T cells for B cell malignancies (Porter et al., 2011; Kochenderfer et al., 2012), other CAR-T cells are under evaluation for hematological malignancies (HM) directed against CD5, CD33, CD70, CD123, CD38, and B cell maturation antigen (BCMA) (Townsend et al., 2018).